Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: A randomized, placebo-controlled, double-blind study

European Journal of Anaesthesiology

Volumn 16, Issue 2, 1999, Pages 118-129

  Chrubasik, S ^a,b   Junck, H ^a   Breitschwerdt, H ^b   Conradt, Ch ^b   Zappe, H ^a  

^a Department of Internal Medicine I ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Analgesia; Harpagophytum procumbens; Low back pain

Indexed keywords

HARPAGOPHYTUM EXTRACT; TRAMADOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL DISEASE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; NEUROLOGICAL COMPLICATION; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANALGESICS, OPIOID; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GLYCOSIDES; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLANT EXTRACTS; PYRANS; TRAMADOL;

EID: 0033051465     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2346.1999.00435.x     Document Type: Article

References (35)

1. Chrubasik S, Wink M. Zur pharmakologischen Wirkung der Teufelskralle (Harpagophytum procumbens). Forsch Komplementärmed 1995; 2: 323-325.
2. Chrubasik S, Sporer F, Wink M. Zum Harpagosidgehalt verschiedener Trocken extraktpulver aus Harpagophytum procumbens. Forsch Komplementärmed 1996; 3: 6-11.
3. Chrubasik S, Sporer F, Wink M. Zum Wirkstoffgehalt in Teezubereitungen aus Harpagophytum procumbens. Forsch Komplementärmed 1996; 3: 116-119.
4. Chrubasik S, Sporer F, Dillmann-Marschner R, Friedmann A, Wink M. Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets. Phytomedicine 1999; (in press).
5. Loew D, Schuster O, Möllerfeld J. Stabilität und biopharmazeutische Qualität, Voraussetzung für Bioverfügbarkeit und Wirksamkeit von Harpagophytum procumbens. In: Loew, D, Rietbrock, N, eds. Phytopharmaka II. Darmstadt: Steinkopf-Verlag, 1996; 88-93.
6. Tippler B, Syrovets T, Loew D, Simmet Th. Harpagophytum procumbens: Wirkung von Extrakten auf die Eicosanoidbiosynthese in lonophor A23187-stimuliertem menschlichem Vollblut. In: Loew, D, Rietbrock, N, eds. Phytopharmaka II. Forschung und klinische Anwendung. Darmstadt: Steinkopf-Verlag, 1996: 95-100.
7. Chrubasik S, Zimpfer Ch, Schutt U, Ziegler R. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine 1996; 3: 1-10.
8. Chrubasik S, Schmidt A, Junck H, Pfisterer M. Wirksamkeit und Wirtschaftlichkeit von Teufelskrallenwurzelextrakt bei Rückenschmerzen: Erste Ergebnisse einer Kohortenstudie. Forsch Komplementärmed 1997; 4: 332-336.
9. Schmelz H, Hämmerle D, Springorum HW. Analgetische Wirkung eines Teufelskrallenwurzel-Extraktes bei verschiedenen chronisch-degenerativen Gelenkerkrankungen. In: Chrubasik, S, Wink, M, eds. Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates-Verlag, 1997: 86-89.
10. Manniche C, Asmussen K, Lauritsen B, Vinterberg H, Kreiner S, Jordan A. Low back rating scale: validation of a tool for assessment of low back pain. Pain 1994; 57: 317-326.
11. Bowsher D, Rigge M, Sopp L. Prevalence of chronic pain in the British population: a telephone survey of 1037 households. Pain Clinic 1991; 4: 223-230.
12. Brattberg G, Thorslund M, Wikman A. The prevalence of pain in a general population. The results of a postal survey in a county of Sweden. Pain 1989; 37: 215-222.
13. Chrubasik S, Junck H, Zappe HA, Stutzke O. A survey on pain complements and health care utilisation in a German population sample. Eur J Anaesthesiol 1998; 15: 397-408.
14. Crook J, Tunks E, Rideout E, Browne G. Epidemiologic comparison of persistent pain sufferers in a specialty pain clinic and in the community. Arch Phys Med Rehabil 1986; 67: 451-455.
15. Rekola KE, Keinanen-Kiukaanniemi S, Takala J. Use of primary health services in sparsely populated country districts by patients with musculoskeletal symptoms: consultations with a physician. J Epidemiol Commun Health 1993; 47: 153-157.
16. Von Korff M, Dworkin SF, Le Resche L, Kruger A. An epidemiologic comparison of pain complaints. Pain 1988; 32: 173-183.
17. Van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of back pain in the Netherlands. Pain 1995; 62: 233-240.
18. Deyo RA. Conservative therapy of low back pain - distinguishing useful from useless therapy. JAMA 1983; 250: 1057-1062.
19. Nachemson AL. Newest knowledge of low back pain. Clin Orthop 1992; 279: 8-21.
20. Koes BW, Scholten RJPM, Mens JMA, Bouter LM. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis 1997; 56: 214-223.
21. Goldie I. A clinical trial with indomethacin (Indomee) in low back pain and sciata. Acta Orthop Scand 1968; 39: 117-128.
22. Weber H, Holme I, Amlie E. The natural course of acute sciata with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 1993; 18: 1433-1438.
23. Rene J, Weinberger M, Mazzuca SA, Brandt KD, Katz BP. Reduction of joint pain in patients with knee osteoarthritis who have received monthly telephone calls from lay personnel and whose medical treatment regimens have remained stable. Arth Rheum 1992; 35: 511-515.
24. Waddel G. Biopsychosocial analysis of low back pain. Baillières Clin Rheumatol 1992; 6: 523-557.
25. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. Pain 1992; 49: 221-230.
26. Kleinke CL, Spangler AS. Predicting treatment outcome of chronic back pain patients in a multidisciplinary pain clinic: methodological issues and treatment implications. Pain 1988; 33: 41-48.
27. Lanes TC, Gauron EF, Spratt KF, Wernimont TJ, Found EM, Weinstein JN. Long-term follow-up of patients with chronic back pain treated in a multidisciplinary rehabilitation program. Spine 1995; 20: 801-806.
28. Love WA, Peck CL. The MMPI and psychological factors in chronic low back pain: a review. Pain 1987; 28: 1-12.
29. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russel RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-754.
30. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992; 92 (Suppl.): 21-24.
31. Griffin MR, Piper J, Daugherty JR, Snowdon M, Ray W. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Int Med 1991; 114: 257-263.
32. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, Murphy M, Vessey MP, Colin-Jones DG. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.
33. Bloom BS. Direct medical costs of disease and gastrointestinal side-effects during treatment for arthritis. Am J Med 1988; 84: 20-24.
34. Greene M, Winickhoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. Arch Int Med 1992; 152: 1995-2002.
35. Levine JS. Mistoprostol and nonsteroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs. Ann Int Med 1995; 123: 309-310.